Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Predictive Factors Of Disease Progression In Parkinson’s Disease In A Tunisian Cohort
Movement Disorders
P14 - Poster Session 14 (8:00 AM-9:00 AM)
3-001

To investigate the predictive factors of cognitive and motor decline in Parkinson’s disease (PD)’s progression.

PD is a highly complex disease. Its progression is very heterogeneous among individuals making it hard to predict its individual trajectories. Factors correlated to cognitive and motor decline are being further investigated in order to discern the clinical phenotype based on baseline clinical characteristics.

A cross-sectional study was conducted in the Department of Neurology of Razi University Hospital including PD patients, diagnosed according to the movement disorder society (MDS) criteria of 2015. Personal history, demographic and clinical characteristics, electrophysiological study of the autonomic system and treatments were specified. To evaluate disease progression, data was assessed at baseline and during follow-up: Unified PD rating scale part III (UPDRS-III) and Hoehn and Yahr scale (HY) for motor decline estimation; Mini-Mental Status Examination (MMSE) for global cognitive performance evaluation and Frontal Assessment Battery (FAB) for evaluation of executive functions.

A total of 150 PD patients were included (sex-ratio=1.17; mean age= 66 years; Mean age of onset= 59.5 years; Mean disease duration = 7.4 years). At baseline, 42.1% were tremor dominant and 46% with postural instability/gait difficulty (PIGD) phenotype. No correlations were found for motor decline. Mean annual rate of cognitive decline of MMSE (0.48+2 points) was correlated to both clinical (including  orthostatic hypotension (p=0.015) and excessive sweating (p=0.015)) and elecrophysiological dysautonomia (parasympathetic function mainly to heart rate variability to deep breathing (p=0.028)  and sympathetic function ( p=0.008)).  

In accordance with previous studies, dysautonomia was a significant factor of cognitive progression in our PD patients. However, motor decline course remained highly unpredictable in our population.
Authors/Disclosures

PRESENTER
No disclosure on file
Arwa Rekik, MD (Sahlouh hospital) No disclosure on file
Saloua Mrabet, MD (Razi University Hospital) Dr. Mrabet has nothing to disclose.
Imen Kacem, MD (Department of Neurology) Dr. Kacem has nothing to disclose.
No disclosure on file
Ben Djebara Mouna No disclosure on file
Riadh Gouider, MD, FÂé¶¹´«Ã½Ó³»­ (Erazi Hospital) Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hikma. The institution of Dr. Gouider has received research support from Clinical Investigation Center. The institution of Dr. Gouider has received research support from Menactrims.